Skip to main content

Table 2 Demographic and clinical characteristics of HER2 positive Breast Cancer Patients

From: Frequency and clinical characteristics of HER2 over-expressed breast cancer in Saudi Arabia: a retrospective study

Demographic and clinical characteristics Total
N = 348
Age at study inclusion (years), n = 348
Mean ± SD 54.07 ± 11.55
Age at breast cancer diagnosis (years), n = 344
Mean ± SD 48.14 ± 11.67
Sex, n = 348
Male 3 (0.9%)
Female 345 (99.1%)
Nationality, n = 348
Saudi Arabian 322 (92.5%)
Other 26 (7.5%)
Body Mass Index (kg/m2), n = 262
Mean ± SD 30.56 ± 6.35
Breast cancer stage based on TNM classification at diagnosis, n = 260
Stage I 19 (7.3%)
Stage II 103 (39.6%)
Stage III A 57 (21.9%)
Stage III B 47 (18.1%)
Stage IV 34 (13.1%)
Metastatic sites, n = 30
Bone 15 (50.0%)
Lung 13 (43.3%)
Liver 13 (43.3%)
Lymph node 4 (13.3%)
Brain 3 (10.0%)
Ovaries 1 (3.3%)
Peritoneum 1 (3.3%)
Primary cancer site, n = 348
Right 175 (50.3%)
Left 164 (47.1%)
Bilateral 8 (2.3%)
Unknown 1 (0.3%)
Performance status, n = 187
Performance status = 0 20 (10.7%)
Performance status = 1 122 (65.2%)
Performance status = 2 31 (16.6%)
Performance status = 3 9 (4.8%)
Performance status = 4 5 (2.7%)
Performance status = 5 0 (0.0%)
Site of biopsy, n = 348
Primary tumor site 328 (94.3%)
Metastatic tumor site 15 (4.3%)
Unknown, not recorded 5 (1.4%)
HER2 test method, n = 348
FISH 53 (15.3%)
IHC 294 (84.7%)
Curative intent surgery performed, n = 348
Yes 293 (84.2%)
No 55 (15.8%)
If Yes, tumor size (cm), n = 264
Mean ± SD 3.5 ± 2.5
Breast cancer pathology, n = 283
Infiltrating ductal carcinoma 263 (92.9%)
Infiltrating lobular carcinoma 0 (0.0%)
Medullary carcinoma 0 (0.0%)
Inflammatory breast cancer 2 (0.7%)
Tubular carcinoma 1 (0.4%)
Mucinous carcinoma 2 (0.7%)
Ductal carcinoma in situ 13 (4.6%)
Invasive ductal carcinoma 2 (0.7%)
Hormone-receptor status, n = 340
ER-/PR- 144 (42.4%)
ER + and/or PR +  196 (57.6%)
Tumor margins, n = 265
Negative 245 (92.5%)
Positive 20 (7.5%)
More than one tumor in the breast, n = 346
Yes 58 (16.8%)
No 288 (83.2%)
If Yes, tumor origin, n = 53
Multifocal breast cancer 33 (62.3%)
Multicentric breast cancer 20 (37.7%)
Lymphovascular invasion, n = 289
Yes 121 (41.9%)
No 168 (58.3%)
Axillary lymph nodes examined (sentinel, sampling, dissection), n = 313
Yes 256 (81.8%)
No 57 (18.2%)
Number of lymph nodes examined, n = 254
Mean ± SD 14.5 ± 11.2
Number of lymph nodes involved, n = 253
Mean ± SD 3.7 ± 7.6
Clinical response at last patient evaluation, n = 217
Stable disease 61 (28.1%)
Progressive disease 72 (33.2%)
Partial response 4 (1.8%)
Complete response 80 (36.9%)
  1. SD standard deviation, FISH fluorescent in situ hybridization, IHC ImmunoHistoChemistry, ER estrogen receptor, PR progesterone receptor